DEXCOM INC (DXCM) Stock Fundamental Analysis

NASDAQ:DXCM • US2521311074

70.02 USD
+4.94 (+7.59%)
At close: Feb 13, 2026
69.67 USD
-0.35 (-0.5%)
After Hours: 2/13/2026, 8:04:11 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Overall DXCM gets a fundamental rating of 6 out of 10. We evaluated DXCM against 185 industry peers in the Health Care Equipment & Supplies industry. DXCM scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DXCM is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year DXCM was profitable.
  • DXCM had a positive operating cash flow in the past year.
  • DXCM had positive earnings in 4 of the past 5 years.
  • Of the past 5 years DXCM 4 years had a positive operating cash flow.
DXCM Yearly Net Income VS EBIT VS OCF VS FCFDXCM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.61%, DXCM belongs to the top of the industry, outperforming 92.97% of the companies in the same industry.
  • DXCM has a Return On Equity of 26.44%. This is amongst the best in the industry. DXCM outperforms 97.30% of its industry peers.
  • DXCM's Return On Invested Capital of 15.72% is amongst the best of the industry. DXCM outperforms 95.68% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for DXCM is above the industry average of 8.75%.
  • The last Return On Invested Capital (15.72%) for DXCM is above the 3 year average (11.25%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 9.61%
ROE 26.44%
ROIC 15.72%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
DXCM Yearly ROA, ROE, ROICDXCM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20 30

1.3 Margins

  • DXCM has a Profit Margin of 15.96%. This is amongst the best in the industry. DXCM outperforms 92.97% of its industry peers.
  • DXCM's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 18.41%, DXCM belongs to the best of the industry, outperforming 90.81% of the companies in the same industry.
  • In the last couple of years the Operating Margin of DXCM has grown nicely.
  • With a decent Gross Margin value of 60.20%, DXCM is doing good in the industry, outperforming 61.62% of the companies in the same industry.
  • DXCM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 18.41%
PM (TTM) 15.96%
GM 60.2%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
DXCM Yearly Profit, Operating, Gross MarginsDXCM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DXCM is still creating some value.
  • DXCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DXCM Yearly Shares OutstandingDXCM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
DXCM Yearly Total Debt VS Total AssetsDXCM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • DXCM has an Altman-Z score of 5.11. This indicates that DXCM is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of DXCM (5.11) is better than 78.92% of its industry peers.
  • The Debt to FCF ratio of DXCM is 2.36, which is a good value as it means it would take DXCM, 2.36 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of DXCM (2.36) is better than 85.95% of its industry peers.
  • DXCM has a Debt/Equity ratio of 0.47. This is a healthy value indicating a solid balance between debt and equity.
  • DXCM's Debt to Equity ratio of 0.47 is in line compared to the rest of the industry. DXCM outperforms 43.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 2.36
Altman-Z 5.11
ROIC/WACC1.64
WACC9.57%
DXCM Yearly LT Debt VS Equity VS FCFDXCM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.3 Liquidity

  • A Current Ratio of 1.56 indicates that DXCM should not have too much problems paying its short term obligations.
  • DXCM has a worse Current ratio (1.56) than 71.89% of its industry peers.
  • DXCM has a Quick Ratio of 1.38. This is a normal value and indicates that DXCM is financially healthy and should not expect problems in meeting its short term obligations.
  • DXCM has a Quick ratio of 1.38. This is in the lower half of the industry: DXCM underperforms 60.00% of its industry peers.
  • The current and quick ratio evaluation for DXCM is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 1.38
DXCM Yearly Current Assets VS Current LiabilitesDXCM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.73% over the past year.
  • The Earnings Per Share has been growing by 19.29% on average over the past years. This is quite good.
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.12%

3.2 Future

  • DXCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.07% yearly.
  • The Revenue is expected to grow by 12.21% on average over the next years. This is quite good.
EPS Next Y35.74%
EPS Next 2Y27.97%
EPS Next 3Y26.78%
EPS Next 5Y22.07%
Revenue Next Year12.62%
Revenue Next 2Y12.5%
Revenue Next 3Y12.3%
Revenue Next 5Y12.21%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
DXCM Yearly Revenue VS EstimatesDXCM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B 10B
DXCM Yearly EPS VS EstimatesDXCM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 37.65, the valuation of DXCM can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of DXCM indicates a somewhat cheap valuation: DXCM is cheaper than 71.89% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.19, DXCM is valued a bit more expensive.
  • A Price/Forward Earnings ratio of 27.73 indicates a quite expensive valuation of DXCM.
  • Based on the Price/Forward Earnings ratio, DXCM is valued a bit cheaper than 72.43% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 28.06, DXCM is valued at the same level.
Industry RankSector Rank
PE 37.65
Fwd PE 27.73
DXCM Price Earnings VS Forward Price EarningsDXCM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • DXCM's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. DXCM is cheaper than 72.43% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of DXCM indicates a rather cheap valuation: DXCM is cheaper than 83.24% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 25.72
EV/EBITDA 23.24
DXCM Per share dataDXCM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

  • DXCM's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of DXCM may justify a higher PE ratio.
  • DXCM's earnings are expected to grow with 26.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.05
PEG (5Y)1.95
EPS Next 2Y27.97%
EPS Next 3Y26.78%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DXCM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DEXCOM INC

NASDAQ:DXCM (2/13/2026, 8:04:11 PM)

After market: 69.67 -0.35 (-0.5%)

70.02

+4.94 (+7.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners99.77%
Inst Owner Change-3.55%
Ins Owners0.19%
Ins Owner Change2.63%
Market Cap27.31B
Revenue(TTM)N/A
Net Income(TTM)720.70M
Analysts84.32
Price Target87.74 (25.31%)
Short Float %3.99%
Short Ratio2.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.05%
Min EPS beat(2)5.32%
Max EPS beat(2)6.77%
EPS beat(4)2
Avg EPS beat(4)-0.91%
Min EPS beat(4)-11.66%
Max EPS beat(4)6.77%
EPS beat(8)6
Avg EPS beat(8)4.61%
EPS beat(12)10
Avg EPS beat(12)13.69%
EPS beat(16)11
Avg EPS beat(16)6.53%
Revenue beat(2)2
Avg Revenue beat(2)0.74%
Min Revenue beat(2)0.61%
Max Revenue beat(2)0.88%
Revenue beat(4)2
Avg Revenue beat(4)0.02%
Min Revenue beat(4)-1.2%
Max Revenue beat(4)0.88%
Revenue beat(8)2
Avg Revenue beat(8)-0.92%
Revenue beat(12)5
Avg Revenue beat(12)-0.38%
Revenue beat(16)6
Avg Revenue beat(16)-0.58%
PT rev (1m)-0.9%
PT rev (3m)-14.09%
EPS NQ rev (1m)0.61%
EPS NQ rev (3m)0.29%
EPS NY rev (1m)0.16%
EPS NY rev (3m)-0.07%
Revenue NQ rev (1m)0.24%
Revenue NQ rev (3m)0.24%
Revenue NY rev (1m)0.06%
Revenue NY rev (3m)0.04%
Valuation
Industry RankSector Rank
PE 37.65
Fwd PE 27.73
P/S 6.05
P/FCF 25.72
P/OCF 18.86
P/B 10.02
P/tB 10.41
EV/EBITDA 23.24
EPS(TTM)1.86
EY2.66%
EPS(NY)2.52
Fwd EY3.61%
FCF(TTM)2.72
FCFY3.89%
OCF(TTM)3.71
OCFY5.3%
SpS11.58
BVpS6.99
TBVpS6.73
PEG (NY)1.05
PEG (5Y)1.95
Graham Number17.1
Profitability
Industry RankSector Rank
ROA 9.61%
ROE 26.44%
ROCE 19.96%
ROIC 15.72%
ROICexc 77.75%
ROICexgc 88.6%
OM 18.41%
PM (TTM) 15.96%
GM 60.2%
FCFM 23.51%
ROA(3y)7.95%
ROA(5y)8.21%
ROE(3y)23.2%
ROE(5y)22.06%
ROIC(3y)11.25%
ROIC(5y)9.23%
ROICexc(3y)35.45%
ROICexc(5y)29.66%
ROICexgc(3y)40.94%
ROICexgc(5y)33.19%
ROCE(3y)14.28%
ROCE(5y)11.73%
ROICexgc growth 3Y55.18%
ROICexgc growth 5Y18.96%
ROICexc growth 3Y50.14%
ROICexc growth 5Y16.58%
OM growth 3Y10.52%
OM growth 5Y8.87%
PM growth 3Y17.27%
PM growth 5Y15.84%
GM growth 3Y-3.98%
GM growth 5Y-0.72%
F-Score5
Asset Turnover0.6
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF 2.36
Debt/EBITDA 1.2
Cap/Depr 158.02%
Cap/Sales 8.55%
Interest Coverage 250
Cash Conversion 134.63%
Profit Quality 147.34%
Current Ratio 1.56
Quick Ratio 1.38
Altman-Z 5.11
F-Score5
WACC9.57%
ROIC/WACC1.64
Cap/Depr(3y)175.34%
Cap/Depr(5y)240.83%
Cap/Sales(3y)9.32%
Cap/Sales(5y)10.84%
Profit Quality(3y)97.76%
Profit Quality(5y)73.64%
High Growth Momentum
Growth
EPS 1Y (TTM)12.73%
EPS 3Y28.82%
EPS 5Y19.29%
EPS Q2Q%0%
EPS Next Y35.74%
EPS Next 2Y27.97%
EPS Next 3Y26.78%
EPS Next 5Y22.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%13.12%
Revenue Next Year12.62%
Revenue Next 2Y12.5%
Revenue Next 3Y12.3%
Revenue Next 5Y12.21%
EBIT growth 1Y28.95%
EBIT growth 3Y30.52%
EBIT growth 5Y33.11%
EBIT Next Year73.63%
EBIT Next 3Y36.37%
EBIT Next 5Y30.37%
FCF growth 1Y112.47%
FCF growth 3Y127.88%
FCF growth 5Y36.21%
OCF growth 1Y93.75%
OCF growth 3Y30.77%
OCF growth 5Y25.76%

DEXCOM INC / DXCM FAQ

Can you provide the ChartMill fundamental rating for DEXCOM INC?

ChartMill assigns a fundamental rating of 6 / 10 to DXCM.


Can you provide the valuation status for DEXCOM INC?

ChartMill assigns a valuation rating of 5 / 10 to DEXCOM INC (DXCM). This can be considered as Fairly Valued.


Can you provide the profitability details for DEXCOM INC?

DEXCOM INC (DXCM) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for DXCM stock?

The Price/Earnings (PE) ratio for DEXCOM INC (DXCM) is 37.65 and the Price/Book (PB) ratio is 10.02.